Notice ID: 137c6a0c2cae4d8eb082ee06fe741592Combined Synopsis/Solicitation
Cepheid 4Plex (XP3COV2/FLU/RSV-10) Test Kits - Albuquerque Service Unit
Archived on August 3, 2023. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 5:30 PM UTC−06:00
- Posted
- July 12, 2023
- Notice type
- Combined Synopsis/Solicitation
- NAICS
- 325413: In-Vitro Diagnostic Substance Manufacturing
- Agency
- Department of Health and Human ServicesINDIAN HEALTH SERVICE
Notice details
- Office
- ALBUQUERQUE AREA INDIAN HEALTH SVC
- Place of performance
- Albuquerque, NM, 87106
- Last updated
- Dec 4, 2025
Identifiers
- Solicitation number
- 75H70723Q00119
- Notice ID
- 137c6a0c2cae4d8eb082ee06fe741592
Description
Amendment 001: To add FAR 52.211-6 Brand Name or Equal (Aug 1999) All other terms below to remain the same. This is a combined synopsis/solicitation for the Indian Health Service (IHS) for commercial items or services prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. The solicitation number is 75H70723Q00119 and is issued as a Request for Quotes (RFQ), unless otherwise indicated herein. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2023-02. The associated North American Industrial Classification System (NAICS) code for this procurement is 325413 with a small business size standard of 1,250 employees. The Albuquerque Area Indian Health Service (AAIHS) has a requirement for the following: Cepheid 4Plex (XP3COV2/FLU/RSV-10) Test kits Albuquerque Service Unit Prospective Offerors are invited to submit proposals in reference to Solicitation No. 75H70723Q00119. The proposal should include, but is not limited to: Quote and vendor information (including UEI number and business size). The Government anticipates awarding one firm-fixed price purchase order with a base year plus four option years. OTHER DETAILS 1. Offer Period - Bid MUST be good for at least 90 calendar days after close of solicitation. 2. SAM Requirement - To be eligible for contract award, vendor must be registered in the System for Award Management (SAM) and must also complete Representations and Certifications at http://www.sam.gov, per FAR 52.204-7. Registration information can be found at www.sam.gov. Vendor must have an active UEI number. 3. Commercial Items Terms and Conditions - The selected Offeror must comply with the following commercial item terms and conditions, which are incorporated herein by reference: FAR 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition; FAR 52.212-3, Offeror Representations and Certifications - Commercial Items - the selected offeror must submit a completed copy of the listed representations and certifications; FAR 52.212-4, Contract Terms and Conditions - Commercial Items; FAR 52.212-5, Contract Terms and Conditions Required To Implement Statutes or Executive Orders-Commercial Items, paragraph (a) and the following clauses in paragraph (b): 52.222-21, 52.222-26, 52.222-35, 52.222-36, 52.222-37, 52.225-13, 52.232-34. The full text of the referenced FAR clauses may be accessed electronically at https://www.acquisition.gov/far/. 4. Terms and Conditions - This is a solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 Streamlined Procedures for Evaluation and Solicitation for Commercial Items, as supplemented with additional information included in this notice. This procurement is being conducted under FAR Part 13, Simplified Acquisition Procedures. 52.204-7, 52.212-3, 52.213-4, 52.222-36. 5. Invoicing- Invoices submitted under any award resulting from this solicitation will be required to utilize the Invoice Processing Platform (IPP) in accordance with HHSAR 352.232-71, Electronic Submission and Processing of Payment Requests (Feb 2022). 6. Payment- All payments by the Government under any associated order shall be made by electronic funds transfer (EFT), per FAR 52.232-33. PROPOSAL SUBMISSION Prospective Offerors are required to submit proposals by: Email to Shandiin.DeWolfe@ihs.gov QUESTIONS? In accordance with FAR 15.201 - Exchanges with Industry, before receipt of proposals, please refer to Solicitation No. 75H70723Q00119 when requesting information regarding the solicitation via e-mail to Shandiin.DeWolfe@ihs.gov, or phone: (505) 256-6755. Proposals will be accepted until 5:30 pm MST on Wednesday, July 19th, 2023.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75H70723Q00119- Market Research
- Combined Synopsis
- Market ResearchJul 5, 2023
Cepheid 4Plex (XP3COV2/FLU/RSV-10) Test Kits - Albuquerque Service Unit
- 2×Combined SynopsisCurrentJul 12, 2023
Cepheid 4Plex (XP3COV2/FLU/RSV-10) Test Kits - Albuquerque Service Unit
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
This innovation from scientists at Los Alamos National Laboratory is a significant improvement on a gold standard protein purification method that gently captures and releases antibodies using mild pH changes, making antibody purification safer, more efficient, and less damaging. The Challenge: Purifying antibodies — vital tools in medicine and research — typically relies on a protein called Protein G that latches onto them. However, getting the antibodies back off this molecular “magnet” requires very acidic conditions, which can damage both the antibodies and Protein G itself. This harsh process risks ruining expensive materials and reducing the effectiveness of critical therapies and tests. Problems Solved: Researchers engineered a pH-switchable version of Protein G that uses gentle changes in acidity (pH) to control when it releases antibodies, it now binds antibodies at a mildly acidic pH and releases at a mildly basic pH — eliminating the need for harsh chemicals. This innovation protects sensitive proteins, improves efficiency, lowers costs, and opens the door for safer, greener, and more effective antibody purification in both labs and industry. Key Advantages: Gentle elution conditions: Antibodies are released at a mild pH (~8.2) instead of harsh acidic conditions (~2.7), reducing damage to both the antibodies and the protein itself. Improved antibody stability and yield: Preserving antibody structure increases reliability and effectiveness, which is especially critical for therapeutic and diagnostic use. Switchable binding mechanism: pH-sensitive histidine residues allow for a controlled "on/off" switch based on pH, improving process control and reproducibility. Cost-effective and scalable: Reduces loss of expensive antibodies and minimizes the need for post-purification repair or replacement, saving money in industrial applications. Market Applications: Biopharmaceuticals Life Sciences Research Bioprocessing and Manufacturing Tools Veterinary and Agricultural Biotech Development Status: TRL 4 US Provisional / Patent No. 10,954,275 LA-UR-25-29451 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search | - | Special Notice | 12/05/2025 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees. This requirement is not set aside for small business. | - | Combined Synopsis | 11/05/2026 |
Please see attached Combined Synopsis/Solicitation. See attached estimated quantities and Questions and Answers. | - | Combined Synopsis | 11/18/2026 |
See attached Sources Sought Notice. | - | Market Research | 10/28/2026 |
Amendment 5 is being issued to re-open the solicitation and proceed with source selection activities. Reinstate Jennifer Gartzke as the point of contact. The attached SF30 contains additional information. | - | Solicitation | 02/15/2026 |
Additional Details
Solicitation Number
75H70723Q00119
Archive Date
Aug 3, 2023
Office Address
ALBUQUERQUE, NM, 87110